Behavior of seeds and soil in the mechanism of metastasis: A deeper understanding

Cancer Science

Volumn 103, Issue 4, 2012, Pages 626-631

  Mathot, Lucy ^a   Stenninger, Johan ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CELECOXIB;

BONE METASTASIS; BRAIN CANCER; BRAIN METASTASIS; BREAST CARCINOGENESIS; CANCER CELL; CANCER THERAPY; CELL HOMING; COLORECTAL CANCER; DISEASE ACTIVITY; DRUG TARGETING; HOST CELL; LIVER METASTASIS; LUNG CARCINOMA; LUNG METASTASIS; LUNG SMALL CELL CANCER; MELANOMA; METASTASIS; PRIORITY JOURNAL; REVIEW; TUMOR CELL;

HUMANS; MUTATION; NEOPLASM METASTASIS; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; TUMOR MICROENVIRONMENT;

EID: 84858997017     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02195.x     Document Type: Review

References (61)

1. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 133: 3.
2. Ribatti D, Mangialardi G, Vacca A. Stephen Paget and the 'seed and soil' theory of metastatic dissemination. Clin Exp Med 2006; 6: 145-9.
3. Woodhouse EC, Chuaqui RF, Liotta LA. General mechanisms of metastasis. Cancer 1997; 80: 1529-37.
4. Chambers AF, Groom AC, MacDonald IC. Metastasis: dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563-72.
5. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9: 274-84.
6. Waghorne C, Thomas M, Lagarde A, Kerbel RS, Breitman ML. Genetic evidence for progressive selection and overgrowth of primary tumors by metastatic cell subpopulations. Cancer Res 1988; 48: 6109-14.
7. Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res 2010; 70: 5649-69.
8. Weiss LA. Pathobiologic overview of metastasis. Semin Oncol 1977; 4: 5-17.
9. Weiss L, Ward PM. Cell detachment and metastasis. Cancer Metastasis Rev 1983; 2: 111-27.
10. Nicolson GL. Cancer metastasis: tumor cell and host organ properties important in metastasis to specific secondary sites. Biochim Biophys Acta 1988; 948: 175-224.
11. Fidler IJ. Metastasis: quantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2′-deoxyuridine. J Natl Cancer Inst 1970; 45: 773-82.
12. Fidler IJ. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res 1975; 35: 218-24.
13. Tarin D et al. Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res 1984; 44: 3584-92.
14. Ewing J. Neoplastic Diseases: A Treatise on Tumors. Philadelphia & London: WB Saunders Co., 1928; 77-89.
15. Barkan D, Green JE, Chambers AF. Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur J Cancer 2010; 46: 1181-8.
16. Hedley BD, Chambers AF. Tumor dormancy and metastasis. Adv Cancer Res 2009; 102: 67-101.
17. Karrison TG, Ferguson DJ, Meier P. Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst 1999; 91: 80-5.
18. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000; 355: 479-85.
19. Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194: 23-8.
20. Welch DR, Tomasovic SP. Implications of tumor progression on clinical oncology. Clin Exp Metastasis 1985; 3: 151-88.
21. Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000; 406: 532-5.
22. Huijbers IJ et al. A role for fibrillar collagen deposition and the collagen internalization receptor endo180 in glioma invasion. PLoS ONE 2010; 5: e9808.
23. Yang J et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117: 927-39.
24. Wallerand H et al. The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers. Urol Oncol 2010; 28: 473-9.
25. Bacac M, Stamenkovic I. Metastatic cancer cell. Annu Rev Pathol 2008; 3: 221-47.
26. Hunter K Welch DR, Liu ET. Genetic background is an important determinant of metastatic potential. Nat Genet 2003; 34: 2-24; author reply 25.
27. Hunter KW. Allelic diversity in the host genetic background may be an important determinant in tumor metastatic dissemination. Cancer Lett 2003; 200: 97-105.
28. Guise T. Examining the metastatic niche: targeting the microenvironment. Semin Oncol 2010; 37(Suppl 2): S2-14.
29. Gancberg D et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002; 13: 1036-43.
30. van de Vijver MJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
31. Kang Y et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3: 537-49.
32. Mulle A et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-6.
33. Cardones AR, Murakami T, Hwang ST. CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via beta(1) integrin. Cancer Res 2003; 63: 6751-7.
34. Epstein RJ. The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies. Nat Rev Cancer 2004; 4: 901-9.
35. Huang EH et al. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res 2009; 155: 231-6.
36. Duda DG et al. CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res 2011; 17: 2074-80.
37. Xu L et al. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res 2009; 69: 7905-10.
38. Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 2005; 10: 169-80.
39. Langley RR, Fidler IJ. The seed and soil hypothesis revisited-the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 2011; 128: 2527-35.
40. Iyer S, Wang ZG, Akhtari M, Zhao W, Seth P. Targeting TGFbeta signaling for cancer therapy. Cancer Biol Ther 2005; 4: 261-6.
41. Barcellos-Hoff MH, Akhurst RJ. Transforming growth factor-beta in breast cancer: too much, too late. Breast Cancer Res 2009; 11: 202.
42. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006; 127: 679-95.
43. Okahara H, Yagita H, Miyake K, Okumura K. Involvement of very late activation antigen 4 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) in tumor necrosis factor alpha enhancement of experimental metastasis. Cancer Res 1994; 54: 3233-6.
44. Langley RR et al. Endothelial expression of vascular cell adhesion molecule-1 correlates with metastatic pattern in spontaneous melanoma. Microcirculation 2001; 8: 335-45.
45. Gosk S, Moos T, Gottstein C, Bendas G. VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. Biochim Biophys Acta 2008; 1778: 854-63.
46. Pantaleo MA et al. Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice. Br J Cancer 2008; 99: 1729-34.
47. Tachimori A, Yamada N, Amano R, Ohira M, Hirakawa K. Combination therapy of S-1 with selective cyclooxygenase-2 inhibitor for liver metastasis of colorectal carcinoma. Anticancer Res 2008; 28: 629-38.
48. Kasper HU et al. COX-2 expression and effects of COX-2 inhibition in colorectal carcinomas and their liver metastases. Anticancer Res 2010; 30: 2017-23.
49. Nakamori S et al. Increased expression of sialyl Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res 1993; 53: 3632-7.
50. Sato M et al. The association of sialyl Lewis(a) antigen with the metastatic potential of human colon cancer cells. Anticancer Res 1997; 17: 3505-11.
51. Brodt P et al. Liver endothelial E-selectin mediates carcinoma cell adhesion and promotes liver metastasis. Int J Cancer 1997; 71: 612-9.
52. Khatib AM, Fallavollita L, Wancewicz EV, Monia BP, Brodt P. Inhibition of hepatic endothelial E-selectin expression by C-raf antisense oligonucleotides blocks colorectal carcinoma liver metastasis. Cancer Res 2002; 62: 5393-8.
53. Li B et al. Comparison of three treatment options for single brain metastasis from lung cancer. Int J Cancer 2000; 90: 37-45.
54. Abbott NJ. Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat 2002; 200: 629-38.
55. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006; 7: 41-53.
56. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006; 12: 895-904.
57. Yano S et al. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res 2000; 60: 4959-67.
58. Yang JC et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-34.
59. Hurwitz H et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
60. Cobleigh MA et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003; 30: 117-24.
61. Morgan SC, Parker CC. Local treatment of metastatic cancer-killing the seed or disturbing the soil? Nat Rev Clin Oncol 2011; 8: 504-6.